The Galleri test catches about 27.5% of early-stage cancers (stages I and II), which means it misses the majority of cancers at the stages when detection matters most. Its strongest selling point is a false positive rate below 1%, meaning it rarely tells healthy people they have cancer. But those two numbers tell very different stories about what “accurate” means in practice, and understanding both is essential before deciding whether this $949 test is worth it.
What the Galleri Test Actually Measures
The Galleri test is a blood draw that looks for fragments of DNA shed by tumors into the bloodstream. Specifically, it analyzes chemical patterns on that DNA to distinguish cancer-related signals from normal ones. When it detects a signal, it also predicts where in the body the cancer is likely located. The test screens for more than 50 types of cancer, over 45 of which have no standard screening test today. That’s the core appeal: it covers cancers like pancreatic, liver, and ovarian that typically go undetected until symptoms appear.
It’s important to know that the Galleri test has not been cleared or approved by the FDA. It’s sold as a laboratory-developed test, meaning GRAIL’s own certified lab processes the samples and has validated its own performance. The lab is certified under federal quality standards (CLIA) and accredited by the College of American Pathologists, but the test hasn’t gone through the FDA’s formal review process.
Sensitivity: How Often It Catches Cancer
Sensitivity is the measure of how reliably a test identifies people who actually have cancer. This is where the Galleri test’s limitations are most apparent. In the large Circulating Cell-free Genome Atlas (CCGA) study, overall sensitivity for stage I and II cancers was just 27.5%. That means roughly three out of four early-stage cancers went undetected.
When researchers narrowed the analysis to 12 cancers considered high unmet need (types with no existing screening and poor outcomes), sensitivity improved to 52.8%. That’s better, but still means nearly half of those cancers were missed. The test performs significantly better at catching advanced cancers, stages III and IV, because larger or more widespread tumors shed more DNA into the blood. But detecting late-stage cancer, while still useful, is far less valuable than catching it early when treatment is most effective.
For context, mammography catches roughly 85% of breast cancers. Colonoscopy detects over 90% of colorectal cancers. The Galleri test is not designed to replace those proven screenings. It’s positioned as a complement to them, casting a wider net across dozens of cancer types that currently have no screening at all.
False Positives and Predictive Value
The test’s false positive rate, below 1% in the CCGA study, sounds reassuringly low. And in percentage terms, it is. If 1,000 people without cancer take the test, fewer than 10 would receive an incorrect “cancer signal detected” result. That’s better than many standard screening tests.
But the more practical question is: if you get a positive result, what are the odds you actually have cancer? Data from clinical studies show that among patients with a positive Galleri result, about 62% were confirmed to have cancer. The other 38% were false alarms. So a positive result means you more likely than not have cancer, but there’s still roughly a one-in-three chance it’s wrong. That 38% of people will undergo additional imaging, biopsies, and significant anxiety before learning they’re cancer-free.
How Well It Pinpoints Cancer Location
When the test does detect a true cancer signal, it also predicts the tissue of origin, essentially telling your doctor where to look. This matters because a vague “you might have cancer somewhere” result would trigger an expensive, stressful full-body workup. The test’s localization accuracy varies by cancer type. For blood cancers specifically, performance is strong: it predicted the correct origin with 99% accuracy for lymphoid cancers and 100% for plasma cell cancers in confirmed cases. Accuracy for solid tumors varies more widely, and an incorrect tissue prediction can lead to unnecessary procedures in the wrong area before the actual source is found.
What the NHS Trial Showed
The largest real-world test of Galleri came from a landmark trial run by the UK’s National Health Service. The NHS-Galleri trial demonstrated a substantial reduction in stage IV cancer diagnoses among participants who received the test, with a corresponding increase in stage I and II detection of deadly cancers. The trial also showed a four-fold higher cancer detection rate compared to standard care alone. These results are encouraging because they suggest the test, despite modest sensitivity numbers, can shift real-world diagnoses toward earlier stages when used as an additional screening layer across a large population.
Cost and Insurance Coverage
The Galleri test costs $949 out of pocket. Most insurance plans do not cover it, and Medicare does not currently reimburse for it either. You’ll need a doctor’s order to get it, and the test is recommended for adults 50 and older or those at elevated cancer risk. GRAIL offers payment plans, but the cost remains a significant barrier for most people considering it as a routine annual screen.
What These Numbers Mean for You
The Galleri test is not a replacement for mammograms, colonoscopies, Pap smears, or any other established cancer screening. Its sensitivity for early-stage cancer is too low to serve as a standalone test for any single cancer type. Where it offers something genuinely new is in screening for the dozens of cancers that currently have no screening test at all. Pancreatic cancer, for example, is almost never caught early. Even a 27.5% detection rate for a cancer with a 0% baseline screening rate represents progress.
The most honest way to think about the Galleri test’s accuracy is this: a negative result provides limited reassurance, because the test misses more early cancers than it finds. A positive result, however, carries real weight, with roughly a 62% chance of confirming actual cancer and strong localization to guide next steps. The test is best understood as an imperfect but unique tool that covers blind spots in cancer screening, not one that replaces the proven tools already available.